Y
Yellowstone Biosciences
Soluble bispecific TCR-based therapies for oncology
About Yellowstone Biosciences
Yellowstone Biosciences is a biotechnology company that spun out of the University of Oxford in June 2024, pioneering a new class of cancer therapies. The company was founded by Professor Paresh Vyas and Julian Hirst. It is built upon two decades of Professor Vyas's research at the University of Oxford, where he serves as Professor of Haematology and is a practicing clinician with a focus on acute myeloid leukaemia (AML). His research has led to the creation of a proprietary biobank with over 10,000 samples from more than 3,000 AML patients, which has been instrumental in identifying a new class of therapeutically targetable antigens. Julian Hirst, the Co-founder and CFO, has over 20 years of experience in investment banking and biotechnology, including roles at Immunocore and MiroBio.
The company launched with a £16.5 million Series A financing from Syncona, a FTSE 250 life sciences investor, which holds a majority stake. This funding is intended to support the company's operational setup, advance its lead program, and explore pipeline expansion. Yellowstone's core technology focuses on developing soluble bispecific T-cell receptor (TCR)-based therapies targeting human leukocyte antigen (HLA) Class II molecules on cancer cells. This approach is designed to selectively kill tumor cells while sparing healthy ones. The company's business model is centered on the research and development of these novel cancer treatments. By leveraging its proprietary biobank and protein engineering capabilities, Yellowstone aims to create therapeutic T-cell bispecific molecules.
The initial focus is on its lead program in AML, a type of leukemia with a high mortality rate and limited standard care options for most patients. Beyond AML, the company's technology has potential applications across a range of common solid tumors that express HLA-II, including ovarian, non-small cell lung, colorectal, prostate, breast, and renal cancers, as well as melanoma. Headquartered in Oxford, UK, Yellowstone operates from a dedicated lab and office space at ARC Oxford, a life sciences cluster.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2024 | $22M | $87M | Syncona | ↗ |
| SPINOUT✓Other financing | Jan 2023 | $0 | — | University of Oxford | ↗ |
Growth signals
Latest recorded traffic for Yellowstone Biosciences is 1.5K monthly website visits, up 167.9% over the last three months. Yellowstone Biosciences's team grew 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yellowstone Biosciences in the Oxford ecosystem
The Yellowstone Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Syncona
Other known investors3 additional known investors
University of Oxford
OUI Startup Incubator
Oxford University Innovation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yellowstone Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yellowstone Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










